Notas de prensa
- Empresa
- General
Mylan completa la adqusición del negocio del negocio de especialidades y genéricos de marca de Abbott en mercados desarrollados no estadounidenses
POTTERS BAR, INGLATERRA, Y PITTSBURGH – 4 de Marzo de 2015 – Mylan N.V. y Mylan Inc. (Nasdaq: MYL) han anunciado hoy la culminación de la adquisición del negocio de especialidades y genéricos de marca de Abbott en mercados desarrollados no estadounidenses (NYSE: ABT).
El Presidente Ejecutivo, Robert J. Coury ha comentado: “El día de hoy marca el comienzo de un nuevo y emocionante capítulo del crecimiento de Mylan. Con la realización de esta operación, nos beneficiaremos de una flexibilidad financiera significativamente mayor, una estructura fiscal optimizada a nivel global y una mejor posición financiera, todo lo cual nos posiciona en una situación de singular privilegio para futuras oportunidades."
En virtud de los términos del acuerdo de la operación ya anunciados, Abbott ha recibido 110 millones de acciones de Mylan N.V., con lo cual los anteriores accionistas de Mylan Inc. poseen ahora alrededor del 78% de Mylan N.V. y Abbott aproximadamente el 22% de dicha entidad. Mylan Inc. y el negocio de especialidades y genéricos de marca de Abbott en mercados desarrollados no estadounidenses han sido reorganizados bajo Mylan N.V., una nueva sociedad anónima constituida en los Países Bajos. Mylan N.V. estará dirigida por el equipo directivo de Mylan Inc. La compañía cotizará en el Nasdaq con el símbolo MYL.
La Consejera Delegada de Mylan, Heather Bresch señala: "Esta operación refuerza de forma significativa nuestra capacidad para perseguir oportunidades adicionales que sean altamente estratégicas y reporten beneficios financieros. Estos nuevos activos se incorporarán a nuestra excepcional plataforma global existente y la estrategia de fuerte crecimiento ya puesta en marcha, y pondrán en mejor situación a la compañía para cumplir nuestra misión de proporcionar a los siete mil millones de habitantes del planeta acceso a medicinas de alta calidad. Esta operación no solo reforzará nuestro perfil financiero, sino que mejorará de forma significativa nuestra presencia geográfica y la plataforma comercial en nuestros principales mercados fuera de EE.UU., creando masa crítica en todos nuestros canales de venta al cliente.
“Hoy damos también la bienvenida a Mylan a alrededor de 3.800 empleados de Abbott, esperando y deseando ver las aportaciones que realizarán a nuestra organización, uniéndose a nuestro objetivo de proporcionar mayores estándares de salud para un mundo mejor.
Forward-Looking Statements
This press release contains "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about the acquisition (the "Transaction") by Mylan N.V. (“Mylan”) of both Mylan Inc. and Abbott Laboratories' non-U.S. developed markets specialty and branded generics business (the "Business"), benefits and synergies of the Transaction, future opportunities for Mylan and products and any other statements regarding Mylan's future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods. These may often be identified by the use of words such as "will", "may", "could", "should", "would", "project", "believe", "anticipate", "expect", "plan", "estimate", "forecast", "potential", "intend", "continue", "target" and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the ability to meet expectations regarding the accounting and tax treatments of the Transaction; changes in relevant tax and other laws; the integration of the Business being more difficult, time-consuming or costly than expected; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) being greater than expected following the Transaction; the retention of certain key employees of the Business being difficult; the possibility that Mylan may be unable to achieve expected synergies and operating efficiencies in connection with the Transaction within the expected time frames or at all and to successfully integrate the Business; expected or targeted future financial and operating performance and results; the capacity to bring new products to market, including but not limited to where Mylan uses its business judgment and decides to manufacture, market and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an "at-risk launch"); the scope, timing and outcome of any ongoing legal proceedings and the impact of any such proceedings on financial condition, results of operations and/or cash flows; the ability to protect intellectual property and preserve intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; the impacts of competition; changes in the economic and financial conditions of the business of Mylan; the inherent challenges, risks and costs in identifying, acquiring and integrating complementary or strategic acquisitions of other companies, products or assets, and in achieving anticipated synergies; uncertainties and matters beyond the control of management and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and related standards, or on an adjusted basis. For more detailed information on the risks and uncertainties associated with Mylan's business activities, see the risks described in Mylan Inc.'s Annual Report on Form 10-K for the year ended Dec. 31, 2013, as updated by Mylan Inc.'s Current Report on Form 8-K filed on Aug. 6, 2014, Mylan Inc.'s Quarterly Report on Form 10-Q for the period ended June 30, 2014, Mylan Inc.'s Quarterly Report on Form 10-Q for the period ended Sept. 30, 2014, and Mylan Inc.’s other filings with the Securities and Exchange Commission (the "SEC"). These risks, as well as other risks associated with Mylan, the Business and the Transaction are also more fully discussed in the Registration Statement on Form S-4 that New Moon B.V. (which has been renamed Mylan N.V. and is referred to herein as Mylan) filed with the SEC on Nov. 5, 2014, as amended on Dec. 9, 2014, and as further amended on Dec. 23, 2014, and in the proxy statement Mylan Inc. filed with the SEC on Dec. 24, 2014, as well as the prospectus Mylan filed with the SEC on Dec. 24, 2014. You can access Mylan’s and Mylan Inc.’s filings with the SEC through the SEC website at www.sec.gov, and Mylan strongly encourages you to do so. Mylan undertakes no obligation to update any statements herein for revisions or changes after the date of this press release.
Mylan es una compañía farmacéutica global comprometida en el establecimiento de nuevos estándares sanitarios. Trabajando juntos en todo el mundo para proporcionar a 7.000 millones de personas acceso a medicamentos de alta calidad, innovamos para satisfacer necesidades no resueltas; convertir la fiabilidad y la excelencia en el servicio en un hábito; hacer lo correcto y no lo sencillo; e influir en el futuro mediante un apasionado liderazgo global. Ofrecemos una creciente gama de más de 1.400 fármacos genéricos y varios medicamentos de marca. Además, ofrecemos una amplia variedad de terapias antirretrovirales, de las cuales dependen aproximadamente el 40% de los pacientes de VIH/SIDA en los países en vías de desarrollo. Gestionamos también uno de los mayores fabricantes de principios activos farmacéuticos y en la actualidad comercializamos productos en alrededor de 145 países y territorios. Nuestra plantilla, de alrededor de 30.000 personas, está dedicada a crear una mejor salud para un mejor mundo, persona a persona. Conozca más en mylan.com or Mylan.es.
